Bristol Myers Squibb Expects Karuna Deal To Be Dilutive To Non-GAAP EPS By Approximately $0.30 In 2024 From The Financing Cost Of Transaction
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb anticipates that its deal with Karuna will result in a dilution of its non-GAAP EPS by around $0.30 in 2024 due to the financing costs associated with the transaction.
December 22, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Karuna is involved in a deal with Bristol Myers Squibb, which is expected to dilute BMY's non-GAAP EPS by $0.30 in 2024.
While the news directly pertains to Bristol Myers Squibb's financials, Karuna is the other party in the deal. The impact on KRTX's stock is less clear without additional details on the deal's benefits for Karuna.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEGATIVE IMPACT
Bristol Myers Squibb's non-GAAP EPS is expected to be diluted by approximately $0.30 in 2024 due to the financing costs of its deal with Karuna.
The expected dilution of non-GAAP EPS is a direct financial impact on Bristol Myers Squibb, likely leading to a negative perception among investors concerned with earnings performance, thus potentially causing a short-term decrease in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100